Cardinal Health's (CAH) performance has been highlighted over a significant period, with its stock outperforming competitors on multiple occasions. The company also keeps the investing community interested through various moves like the announcement of a dividend increase, as well as its robust Q3 2024 earnings. However, the story isn't all butterflies and rainbows; CAH shares exhibited some volatility and underperformance compared to other market players. There was also an emphasis on the non-renewal of Cardinal Health's contract with OptumRx which caused some disturbances. Despite such challenges, CAH seems optimistic, reaffirming its Fiscal 2024 non-GAAP EPS guidance and long-term targets. It acquired Specialty Networks for $1.2B to strengthen its specialty Pharma arm. Further, it recalls kits containing Shenli's syringes after FDA warnings, demonstrating compliance to safety regulations. CAH remains a favorite among institutional investors, with an 89% institutional ownership. Analysts & research groups consider CAH a strong value stock for the long-term and remains a good addition to portfolios. But caution is advised as insiders sold USD 9.7m in stock, signaling potential weaknesses. Nevertheless, CAH continues to grow into its valuation and streamline its operations.
Cardinal Health CAH News Analytics from Fri, 03 Nov 2023 07:00:00 GMT to Sun, 28 Jul 2024 13:55:51 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor 2
